The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

In general, tumor necrosis factor-alpha (TNF-α) antagonists and filgotinib were also more effective than ozanimod for achieving symptomatic remission at week 2. In addition, ustekinumab and ...

Phase 3 trials of tofacitinib and upadacitinib and a phase 2 trial of filgotinib all showed good therapeutic response in adults with AS. Baricitinib has no clinical development program.

Antitumour necrosis factor alpha (anti-TNFα) agents include infliximab, adalimumab, golimumab, AVX-470 and OPRX-106. Janus kinase (JAK) inhibitors: tofacitinib, filgotinib and upadacitinib.

The risk-benefit profile of upadacitinib for rheumatoid arthritis “remains favorable” through 5 years, ... tofacitinib, baricitinib and filgotinib, are [targeted synthetic DMARDs] ...

In the upadacitinib induction studies, corticosteroids were tapered after week 4, and most patients were off corticosteroids by week 11, before evaluation of clinical and endoscopic efficacy.

Besides tofacitinib, baricitinib (Olumiant) and upadacitinib (Rinvoq) are approved -- the latter also selective for JAK1/2. Earlier this year, Galapagos sold the filgotinib business to the Italian ...

Antitumour necrosis factor alpha (anti-TNFα) agents include infliximab, adalimumab, golimumab, AVX-470 and OPRX-106. Janus kinase (JAK) inhibitors: tofacitinib, filgotinib and upadacitinib ...

Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn disease, including those previously treated with advanced therapies ...

3.1 Upadacitinib is a type of treatment called a Janus kinase (JAK) inhibitor. It has a marketing authorisation for treating moderately to severely active ulcerative colitis when conventional or ...

Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration ...